Ligaria cuneifolia flavonoid fractions modulate growth of normal lymphocytes, tumor and MDR tumor cells

CERDÁ ZOLEZZI PAULA; FERNÁNDEZ TERESA,; CAVALIERE VICTORIA; GRECZANIK SOFÍA,; AULICINO PAULA,; CALDAS LOPES ELOISI,; WAGNER MARCELO; HAJOS SILVIA; GUNI ALBERTO; ALVAREZ ELIDA.

IMMUNOBIOLOGY.

Elsiever

Lugar: Germany; Año: 2005 vol. 209 p. 737 - 750

0171-2985

Flavonoids are ubiquitous compounds present in plant extracts. They represent a major active component of the plant extract and are often known for their anti-inflammatory and anti-tumor effects. Previously, we demonstrated that Ligaria cuneifolia (R et P) Tiegh. (Loranthaceae) extracts inhibit proliferation of murine mitogen-activated lymphocytes as well as murine T leukaemia (LB) and breast tumor cells (MMT). The aim of this study was to assess the anti-proliferative and pro-apoptotic activities of three separate flavonoid fractions derived from L. cuneifolia whole extract (aqueous, methanolic and ethyl acetate) on normal and tumor cells. This was performed as a bio-guided approach leading to the isolation and identification of the active compounds responsible for the effects observed with the whole extract. Results showed that the three fractions differed in the amount and type of compounds found. Only the ethyl acetate flavonoid fraction (100 microg/ml) was able to inhibit significantly the proliferation of Con A stimulated splenocytes or LB and MMT cells. Inhibition of proliferation was mediated by apoptosis as determined by morphology and DNA hypodiploidy. The ethyl acetate fraction modified mRNA expression of IL-2, IL-10 and TGF-beta, while the methanol fraction only modified IL-10 mRNA on LB cells. Our results show that the ethyl acetate flavonoid fraction contains the most active compound/s and is the potential candidate to isolate the active compound/s responsible for the effects observed with L. cuneifolia whole extract. PMID: 15969450 [PubMed - indexed for MEDLINE]